MX358679B - Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo. - Google Patents

Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo.

Info

Publication number
MX358679B
MX358679B MX2014007033A MX2014007033A MX358679B MX 358679 B MX358679 B MX 358679B MX 2014007033 A MX2014007033 A MX 2014007033A MX 2014007033 A MX2014007033 A MX 2014007033A MX 358679 B MX358679 B MX 358679B
Authority
MX
Mexico
Prior art keywords
preparation
pyrrole
membered heteroaryl
heteroaryl ring
method therefor
Prior art date
Application number
MX2014007033A
Other languages
English (en)
Other versions
MX2014007033A (es
Inventor
Zhang Xuejun
Dong Qing
Liu Bonian
Zhu Yaoping
Li Xiaotao
Lan Jiong
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2014007033A publication Critical patent/MX2014007033A/es
Publication of MX358679B publication Critical patent/MX358679B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)

Abstract

La presente invención se refiere a un derivado de anillo de heteroarilo de seis miembros de pirrol, el método de preparación del mismo, y los usos médicos del mismo. Específicamente, la presente invención se refiere a un nuevo derivado de anillo de heteroarilo de seis miembros de pirrol como se representa en la fórmula (I), el método de preparación para el mismo, una composición médica que comprende el derivado, y un agente terapéutico que usa el mismo, y en particular los usos como un inhibidor de JAK y un inmunosupresor. Los sustituyentes en la fórmula (I) tienen las mismas definiciones como en la descripción.
MX2014007033A 2011-12-21 2012-12-19 Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo. MX358679B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110434071 2011-12-21
PCT/CN2012/086922 WO2013091539A1 (zh) 2011-12-21 2012-12-19 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2014007033A MX2014007033A (es) 2014-09-16
MX358679B true MX358679B (es) 2018-08-31

Family

ID=48667710

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007033A MX358679B (es) 2011-12-21 2012-12-19 Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo.

Country Status (23)

Country Link
US (3) US9527851B2 (es)
EP (1) EP2796460B1 (es)
JP (1) JP6075736B2 (es)
KR (1) KR102032934B1 (es)
CN (1) CN103415520B8 (es)
AU (1) AU2012357296B2 (es)
BR (1) BR112014014325B1 (es)
CA (1) CA2857977C (es)
CY (1) CY1121161T1 (es)
DK (1) DK2796460T3 (es)
ES (1) ES2682755T3 (es)
HR (1) HRP20181201T1 (es)
HU (1) HUE039111T2 (es)
LT (1) LT2796460T (es)
MX (1) MX358679B (es)
PL (1) PL2796460T3 (es)
PT (1) PT2796460T (es)
RS (1) RS57621B1 (es)
RU (1) RU2618673C2 (es)
SI (1) SI2796460T1 (es)
SM (1) SMT201800497T1 (es)
TW (1) TWI601728B (es)
WO (1) WO2013091539A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180061T1 (hr) * 2012-07-17 2018-02-23 Glaxosmithkline Intellectual Property (No. 2) Limited Indolkarbonitrili kao selektivni modulatori androgenskih receptora
EP3290421B1 (en) * 2013-02-22 2019-01-02 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
EP3006445B1 (en) * 2013-06-07 2017-11-15 Jiangsu Hengrui Medicine Co. Ltd. Bisulfate of janus kinase (jak) inhibitor and preparation method therefor
EP3461827B1 (en) 2013-09-26 2022-02-23 Cadent Therapeutics, Inc. Selective octahydro-cyclopenta[c]pyrrole negative modulators of nr2b
ES2654051T3 (es) 2013-12-05 2018-02-12 Pfizer Inc. Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
KR101710127B1 (ko) * 2014-08-29 2017-02-27 한화제약주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
CN105566327A (zh) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
JP6851572B2 (ja) * 2014-11-05 2021-03-31 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． Ｊａｋキナーゼ阻害剤の硫酸水素塩の結晶形およびその製造方法
CN105712998B (zh) * 2014-12-05 2019-12-13 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
DK3305788T3 (da) * 2015-05-29 2020-09-28 Wuxi Fortune Pharmaceutical Co Ltd Janus-kinase-hæmmer
US10786507B2 (en) * 2016-02-19 2020-09-29 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
BR112019008812A2 (pt) * 2016-11-23 2019-07-16 Jiangsu Hengrui Medicine Co método de preparação para e intermediário de derivado de pirrolo anel heteroaromático de seis elementos
CN110267950A (zh) 2016-12-22 2019-09-20 拜耳作物科学股份公司 取代的杂芳基吡咯酮及其盐和其作为除草活性物质的用途
CN110337436A (zh) 2016-12-22 2019-10-15 拜耳作物科学股份公司 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途
CN108779122B (zh) * 2017-01-20 2021-01-15 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US11266640B2 (en) * 2017-09-20 2022-03-08 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
ES3064093T3 (en) 2017-10-20 2026-04-22 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
US11241378B2 (en) 2017-11-20 2022-02-08 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical JAK kinase inhibitor and diethylene glycol composition for topical administration and preparation method therefor
JP2021507894A (ja) 2017-12-19 2021-02-25 バイエル、アクチエンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換されたｎ−ヘテロシクリル−およびｎ−ヘテロアリール−テトラヒドロピリミジノンならびにその塩、ならびに除草活性物質としてのその使用
CA3093706A1 (en) 2018-03-21 2019-09-26 Xibin Liao Jak inhibitors
WO2020052575A1 (zh) * 2018-09-12 2020-03-19 江苏恒瑞医药股份有限公司 Jak激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途
CN110950842B (zh) * 2018-09-27 2023-06-20 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
EP3877389A4 (en) * 2018-11-05 2022-07-13 Avista Pharma Solutions, Inc. Chemical compounds
CN111205290B (zh) * 2018-11-22 2021-10-08 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的结晶形式及其制备方法
CN111320633B (zh) * 2018-12-14 2022-09-27 中国医药研究开发中心有限公司 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
KR102737181B1 (ko) 2019-03-14 2024-12-02 상하이 시너지 파마슈티컬 사이언시스 코., 엘티디. Jak 억제제 및 그 제조방법과 의약분야에서의 응용
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110028509B (zh) * 2019-05-27 2020-10-09 上海勋和医药科技有限公司 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途
AU2020338043B2 (en) * 2019-08-26 2025-12-18 Chemwerth, Inc. Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021115286A1 (zh) * 2019-12-10 2021-06-17 成都倍特药业股份有限公司 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023068213A (ja) * 2020-03-31 2023-05-17 慶應義塾 炎症性腸疾患処置剤、及び、アミド化合物又はその塩
WO2021201126A1 (ja) * 2020-03-31 2021-10-07 富士フイルム株式会社 アミド化合物又はその塩、医薬組成物、及び、ヒストン脱アセチル化酵素阻害剤
CN113698404B (zh) * 2020-05-21 2023-06-16 江苏恒瑞医药股份有限公司 一种低溶剂残留的六氢环戊并[c]吡咯-2(1H)-甲酰胺化合物及其制备方法
CN116600786A (zh) 2020-07-28 2023-08-15 阿尔库缇斯生物疗法股份有限公司 含有jak抑制剂和月桂醇聚醚-4的局部制剂
JP2023544495A (ja) * 2020-09-11 2023-10-24 ガルデルマ ホールディング エスエー 新規ｊａｋ阻害剤化合物、その合成方法、及びその使用
MX2023005106A (es) 2020-10-29 2023-05-23 Arcutis Biotherapeutics Inc Metodos para tratar lesiones de vitiligo que tienen eficacia mejorada.
US11628177B2 (en) 2020-11-17 2023-04-18 Arcutis Biotherapeutics, Inc. Compositions and methods for deep dermal drug delivery
WO2022117075A1 (zh) * 2020-12-04 2022-06-09 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途
US12599604B2 (en) 2020-12-11 2026-04-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Application of JAK inhibitor in kidney disease
CN112933095A (zh) * 2020-12-29 2021-06-11 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
TW202320788A (zh) * 2021-08-12 2023-06-01 大陸商江蘇恒瑞醫藥股份有限公司 用於治療或預防抗宿主病的吡咯并六元雜芳物
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
CA3237871A1 (en) 2021-11-11 2023-05-19 David W. Osborne Pharmaceutical compositions of spironolactone for deep dermal drug delivery
JP2024544404A (ja) * 2021-12-15 2024-11-29 アーキュティス・バイオセラピューティクス・インコーポレーテッド Ｓｈｒ０３０２の安定な製剤
WO2023151069A1 (zh) * 2022-02-14 2023-08-17 湖南南新制药股份有限公司 吡咯并[2,3-d]六元杂芳环衍生物、其制备方法和药物用途
WO2024114814A1 (en) * 2022-12-02 2024-06-06 Onquality Pharmaceuticals China Ltd Jak inhibitors, pharmaceutical compositions, and therapeutic applications
CN120641104A (zh) * 2023-02-07 2025-09-12 瑞石生物医药有限公司 一种局部给药的药物组合物、其制备方法及应用
CN121652132A (zh) * 2026-02-09 2026-03-13 山东国邦药业有限公司 一种羟乙基哌嗪联产三乙烯二胺的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0278659A (ja) * 1988-09-12 1990-03-19 Shionogi & Co Ltd アザビシクロアルカン類化合物
US5521193A (en) 1992-06-24 1996-05-28 G. D. Searle & Co. Benzimidazole compounds
US5527910A (en) * 1992-12-30 1996-06-18 Cheil Foods & Chemicals, Inc. Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria
PL198640B1 (pl) * 1998-06-19 2008-07-31 Pfizer Prod Inc Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków
EA006227B1 (ru) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
YU55902A (sh) * 2000-01-24 2006-01-16 Warner-Lambert Company 3-aminohinazolin-2,4-dioni kao antibakterijska sredstva
EA006153B1 (ru) * 2000-06-26 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
AU2004226824B2 (en) 2003-04-04 2008-05-01 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
EP1631558A1 (en) 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
US7381738B2 (en) * 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
JP2008507543A (ja) * 2004-07-22 2008-03-13 グラクソ　グループ　リミテッド 抗細菌剤
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006067614A2 (en) * 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
EP1844050B1 (en) * 2005-02-03 2009-01-14 Vertex Pharmaceuticals, Inc. Pyrrolopyrimidines useful as inhibitors of protein kinase
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
CN101230058A (zh) * 2007-01-23 2008-07-30 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
US8183245B2 (en) * 2007-10-25 2012-05-22 Merck Sharp & Dohme Corp. Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1
US8304411B2 (en) 2008-01-23 2012-11-06 Jiangsu Hansoh Pharmaceutical Co., Ltd. Dicycloazaalkane derivates, preparation processes and medical uses thereof
TW200944523A (en) * 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
US20120028990A1 (en) * 2009-04-16 2012-02-02 Msd K.K 3 aryl or heteroaryl-substituted indole derivative
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
WO2012058645A1 (en) * 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
US8987268B2 (en) * 2011-03-17 2015-03-24 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2012171863A1 (en) 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists

Also Published As

Publication number Publication date
CY1121161T1 (el) 2020-05-29
BR112014014325A2 (pt) 2021-05-25
SI2796460T1 (sl) 2018-10-30
CA2857977C (en) 2020-10-20
HK1187615A1 (zh) 2014-04-11
LT2796460T (lt) 2018-10-10
EP2796460B1 (en) 2018-07-04
AU2012357296A1 (en) 2014-07-03
JP2015500845A (ja) 2015-01-08
HRP20181201T1 (hr) 2018-10-19
TWI601728B (zh) 2017-10-11
KR20140103300A (ko) 2014-08-26
MX2014007033A (es) 2014-09-16
CN103415520B (zh) 2016-01-20
US20170044171A1 (en) 2017-02-16
SMT201800497T1 (it) 2018-11-09
WO2013091539A1 (zh) 2013-06-27
PL2796460T3 (pl) 2018-12-31
BR112014014325B1 (pt) 2022-06-07
TW201326176A (zh) 2013-07-01
PT2796460T (pt) 2018-11-05
US20140336207A1 (en) 2014-11-13
US20180222912A1 (en) 2018-08-09
CN103415520A (zh) 2013-11-27
RU2014128307A (ru) 2016-02-10
DK2796460T3 (en) 2018-08-27
CA2857977A1 (en) 2013-06-27
RS57621B1 (sr) 2018-11-30
KR102032934B1 (ko) 2019-10-16
US9527851B2 (en) 2016-12-27
EP2796460A4 (en) 2015-05-20
EP2796460A1 (en) 2014-10-29
RU2618673C2 (ru) 2017-05-10
AU2012357296B2 (en) 2017-04-13
ES2682755T3 (es) 2018-09-21
US10428074B2 (en) 2019-10-01
JP6075736B2 (ja) 2017-02-08
CN103415520B8 (zh) 2017-04-05
HUE039111T2 (hu) 2018-12-28

Similar Documents

Publication Publication Date Title
PH12020550552A1 (en) Inhibitors of hepatitis c virus
CY1121161T1 (el) Εξαμελες παραγωγο πυρρολιου ετεροαρυλικου δακτυλιου, μεθοδος παρασκευης αυτου και ιατρικες χρησεις αυτου
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
WO2012019426A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
MX368263B (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
WO2012019430A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
NZ709211A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
IN2015DN01119A (es)
MX349373B (es) Nuevos derivados de pirazina.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MX364400B (es) Compuestos de tetraciclina.
GEP201606566B (en) Isoxazolidine derivatives
GB201305247D0 (en) Amide Compounds
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
CU20110108A7 (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos

Legal Events

Date Code Title Description
FG Grant or registration